Résumé
Background@#Upadacitinib is an oral Janus kinase1 (JAK1)-selective inhibitor, which showed a quick and significant effect on patients with atopic dermatitis in several phase 3 clinical studies. Although, an increasing number of studies have reported data on the real-world efficacy and safety of upadacitinib for the treatment of atopic dermatitis, no studies have yet been published in Korea. @*Objective@#We assessed the real-world efficacy and safety of upadacitinib for the treatment of atopic dermatitis in Korean patients. @*Methods@#A total of 17 patients with atopic dermatitis who received 15 mg of oral upadacitinib everyday for 16 weeks, were included in this retrospective single-center study. Based on electronic medical records, the clinical characteristics, Eczema Area and Severity Index (EASI) score, and adverse events were investigated. @*Results@#The mean EASI score was significantly reduced at 4 weeks of upadacitinib treatment (8.81±9.00) and gradually reduced at week 8 (5.70±7.38), week 12 (4.55±6.23), and week 16 (4.58±6.74) (p＜0.001). At week 16, 61.54%, 30.77%, and 15.38% of patients achieved EASI 75, EASI 90, and EASI 100 responses, respectively. There was no statistically significant difference between EASI 75 and EASI 90 by age or gender at week 16 (p＞0.05). A total of 13 people (76.5%) had adverse events, of which acne was the most common. In all patients, the symptoms were mild and self-limited, and no patient discontinued treatment. @*Conclusion@#Upadacitinib was effective and safe for Korean patients with atopic dermatitis in real-world clinical practice.
Résumé
No abstract available.
Sujets)
Humains , Histiocytose , Mycobacterium haemophilum , MycobacteriumRésumé
No abstract available.
Résumé
No abstract available.
Sujets)
Granulocytes éosinophiles , Syndrome hyperéosinophilique , MyositeRésumé
No abstract available.
Résumé
Melanonychia is a darkening of the nails and its importance is that it may indicate the presence of a subungual malignant melanoma. Because the incidence of malignant melanoma is quite small in children, clinicians have had difficulties as to whether or not to perform a nail matrix biopsy in the children with melanonychia. Herein, we report the case of a 6-year-old boy that presented with melanonychia, which was determined to be confirmed melanoma in situ.